NLRP3 and COVID-19: The infection–immune–inflammatory core of acute COVID-19, the development of NLRP3, a mild chronic inflammatory response, increased nitro-oxidative stress, lowered antioxidant defenses, and total Ca levels can be considered new drug targets to treat the physio-affective symptoms of long COVID.